NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Pacira BioSciences Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Pacira BioSciences is a biopharmaceutical company that develops non-opioid pain management therapies. The company commercializes EXPAREL for postsurgical pain, ZILRETTA for osteoarthritis knee pain, and iovera°, a cryoanalgesia device. Pacira also advances a pipeline including PCRX-201, a gene therapy candidate in clinical development.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Pacira BioSciences Inc stock.
Overvalued: intrinsic value $29.68 per share, market price $36.48, margin of safety -22.9% (as of 2026-11-17).
Discounting its cash flows at 6.8% (average of 3 methods) values the shares at $29.68; the price of $36.48 is 23% above that value, and 84% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
14 more in this industry show a wider margin of safety.
PCRX is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 6.8% (average of 3 methods) values the shares at $29.68; the price of $36.48 is 23% above that value, and 84% of that value comes from beyond year five.
$29.68 per share (as of the 2026-11-17 close), against a market price of $36.48. That is a margin of safety of -22.9%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.